Therapeutic potential of the Mycobacterium tuberculosis mycolic acid transporter, MmpL3

Wei Li, Andrés Obregón-Henao, Joshua B. Wallach, E. Jeffrey North, Richard E. Lee, Mercedes Gonzalez-Juarrero, Dirk Schnappinger, Mary Jackson

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

In recent years, whole-cell-based screens for novel small molecule inhibitors active against Mycobacterium tuberculosis in culture followed by the whole-genome sequencing of spontaneous resistant mutants have identified multiple chemical scaffolds thought to kill the bacterium through the inactivation of the mycolic acid transporter, MmpL3. Consistent with the fact that MmpL3 is required for the formation of the mycobacterial outer membrane, we have conclusively shown in this study, using conditionally regulated knockdown mutants, that mmpL3 is required for the replication and viability of M. tuberculosis, both under standard laboratory growth conditions and during the acute and chronic phases of infection in mice. Speaking for the vulnerability of this target, silencing mmpL3 had a rapid bactericidal effect on actively replicating cells in vitro and reduced by 3 to 5 logs in less than 4 weeks the bacterial loads of acutely and chronically infected mouse lungs, respectively. Depletion of MmpL3 further rendered M. tuberculosis hypersusceptible to MmpL3 inhibitors. The exquisite vulnerability of MmpL3 at all stages of the infection establishes this transporter as an attractive new target with the potential to improve and shorten current drug-susceptible and drug-resistant tuberculosis chemotherapies.

Original languageEnglish (US)
Pages (from-to)5198-5207
Number of pages10
JournalAntimicrobial Agents and Chemotherapy
Volume60
Issue number9
DOIs
StatePublished - Sep 1 2016

Fingerprint

Mycolic Acids
Mycobacterium tuberculosis
Multidrug-Resistant Tuberculosis
Bacterial Load
Infection
Therapeutics
Genome
Bacteria
Drug Therapy
Lung
Membranes
Growth
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Li, W., Obregón-Henao, A., Wallach, J. B., North, E. J., Lee, R. E., Gonzalez-Juarrero, M., ... Jackson, M. (2016). Therapeutic potential of the Mycobacterium tuberculosis mycolic acid transporter, MmpL3. Antimicrobial Agents and Chemotherapy, 60(9), 5198-5207. https://doi.org/10.1128/AAC.00826-16

Therapeutic potential of the Mycobacterium tuberculosis mycolic acid transporter, MmpL3. / Li, Wei; Obregón-Henao, Andrés; Wallach, Joshua B.; North, E. Jeffrey; Lee, Richard E.; Gonzalez-Juarrero, Mercedes; Schnappinger, Dirk; Jackson, Mary.

In: Antimicrobial Agents and Chemotherapy, Vol. 60, No. 9, 01.09.2016, p. 5198-5207.

Research output: Contribution to journalArticle

Li, W, Obregón-Henao, A, Wallach, JB, North, EJ, Lee, RE, Gonzalez-Juarrero, M, Schnappinger, D & Jackson, M 2016, 'Therapeutic potential of the Mycobacterium tuberculosis mycolic acid transporter, MmpL3', Antimicrobial Agents and Chemotherapy, vol. 60, no. 9, pp. 5198-5207. https://doi.org/10.1128/AAC.00826-16
Li, Wei ; Obregón-Henao, Andrés ; Wallach, Joshua B. ; North, E. Jeffrey ; Lee, Richard E. ; Gonzalez-Juarrero, Mercedes ; Schnappinger, Dirk ; Jackson, Mary. / Therapeutic potential of the Mycobacterium tuberculosis mycolic acid transporter, MmpL3. In: Antimicrobial Agents and Chemotherapy. 2016 ; Vol. 60, No. 9. pp. 5198-5207.
@article{75b584a7f2ca485e9c6e4173d62ef323,
title = "Therapeutic potential of the Mycobacterium tuberculosis mycolic acid transporter, MmpL3",
abstract = "In recent years, whole-cell-based screens for novel small molecule inhibitors active against Mycobacterium tuberculosis in culture followed by the whole-genome sequencing of spontaneous resistant mutants have identified multiple chemical scaffolds thought to kill the bacterium through the inactivation of the mycolic acid transporter, MmpL3. Consistent with the fact that MmpL3 is required for the formation of the mycobacterial outer membrane, we have conclusively shown in this study, using conditionally regulated knockdown mutants, that mmpL3 is required for the replication and viability of M. tuberculosis, both under standard laboratory growth conditions and during the acute and chronic phases of infection in mice. Speaking for the vulnerability of this target, silencing mmpL3 had a rapid bactericidal effect on actively replicating cells in vitro and reduced by 3 to 5 logs in less than 4 weeks the bacterial loads of acutely and chronically infected mouse lungs, respectively. Depletion of MmpL3 further rendered M. tuberculosis hypersusceptible to MmpL3 inhibitors. The exquisite vulnerability of MmpL3 at all stages of the infection establishes this transporter as an attractive new target with the potential to improve and shorten current drug-susceptible and drug-resistant tuberculosis chemotherapies.",
author = "Wei Li and Andr{\'e}s Obreg{\'o}n-Henao and Wallach, {Joshua B.} and North, {E. Jeffrey} and Lee, {Richard E.} and Mercedes Gonzalez-Juarrero and Dirk Schnappinger and Mary Jackson",
year = "2016",
month = "9",
day = "1",
doi = "10.1128/AAC.00826-16",
language = "English (US)",
volume = "60",
pages = "5198--5207",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "9",

}

TY - JOUR

T1 - Therapeutic potential of the Mycobacterium tuberculosis mycolic acid transporter, MmpL3

AU - Li, Wei

AU - Obregón-Henao, Andrés

AU - Wallach, Joshua B.

AU - North, E. Jeffrey

AU - Lee, Richard E.

AU - Gonzalez-Juarrero, Mercedes

AU - Schnappinger, Dirk

AU - Jackson, Mary

PY - 2016/9/1

Y1 - 2016/9/1

N2 - In recent years, whole-cell-based screens for novel small molecule inhibitors active against Mycobacterium tuberculosis in culture followed by the whole-genome sequencing of spontaneous resistant mutants have identified multiple chemical scaffolds thought to kill the bacterium through the inactivation of the mycolic acid transporter, MmpL3. Consistent with the fact that MmpL3 is required for the formation of the mycobacterial outer membrane, we have conclusively shown in this study, using conditionally regulated knockdown mutants, that mmpL3 is required for the replication and viability of M. tuberculosis, both under standard laboratory growth conditions and during the acute and chronic phases of infection in mice. Speaking for the vulnerability of this target, silencing mmpL3 had a rapid bactericidal effect on actively replicating cells in vitro and reduced by 3 to 5 logs in less than 4 weeks the bacterial loads of acutely and chronically infected mouse lungs, respectively. Depletion of MmpL3 further rendered M. tuberculosis hypersusceptible to MmpL3 inhibitors. The exquisite vulnerability of MmpL3 at all stages of the infection establishes this transporter as an attractive new target with the potential to improve and shorten current drug-susceptible and drug-resistant tuberculosis chemotherapies.

AB - In recent years, whole-cell-based screens for novel small molecule inhibitors active against Mycobacterium tuberculosis in culture followed by the whole-genome sequencing of spontaneous resistant mutants have identified multiple chemical scaffolds thought to kill the bacterium through the inactivation of the mycolic acid transporter, MmpL3. Consistent with the fact that MmpL3 is required for the formation of the mycobacterial outer membrane, we have conclusively shown in this study, using conditionally regulated knockdown mutants, that mmpL3 is required for the replication and viability of M. tuberculosis, both under standard laboratory growth conditions and during the acute and chronic phases of infection in mice. Speaking for the vulnerability of this target, silencing mmpL3 had a rapid bactericidal effect on actively replicating cells in vitro and reduced by 3 to 5 logs in less than 4 weeks the bacterial loads of acutely and chronically infected mouse lungs, respectively. Depletion of MmpL3 further rendered M. tuberculosis hypersusceptible to MmpL3 inhibitors. The exquisite vulnerability of MmpL3 at all stages of the infection establishes this transporter as an attractive new target with the potential to improve and shorten current drug-susceptible and drug-resistant tuberculosis chemotherapies.

UR - http://www.scopus.com/inward/record.url?scp=84983509267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983509267&partnerID=8YFLogxK

U2 - 10.1128/AAC.00826-16

DO - 10.1128/AAC.00826-16

M3 - Article

VL - 60

SP - 5198

EP - 5207

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 9

ER -